diagnost tool
takeaway road buy pt
recent host day investor meet htg ceo tj johnson cfo shaun
mcmean came away feel posit compani increas visibl
busi posit precis medicin enabl less-crowd rna
profil market addit call htg deliv encourag updat
highlight continu progress toward sign one companion diagnost
agreement pharma htg stock ytd pull back
high late septemb investor abl invest micro-cap handl short-
term volatil think htg inexpens way invest precis medicin
pure-play trade revenu estim
respect htg trade discount dna-enabl
protein biomark enabl reiter buy rate pt
new cso hire look expand htg capabl htg recent hire dr maureen
cronin svp/chief scientif offic dr cronin previous serv execut
director strateg inform manag celgen svp research product
develop foundat medicin vice-president translat research senior
director technolog develop genom health expect dr cronin
instrument develop genom health oncotyp dx breast test help
htg expand applic new test panel indic includ breast cancer
expect go/no go decis htg two pharma develop program
soon htg deliv two custom cdx assay pharma collabor one
bristol-my squibb anoth unnam lead pharma compani use
retrospect studi across multipl clinic trial diseas indic htg expect
hear next quarter mayb sooner whether pharma collabor
intend submit drug fda time htg would submit cdx assay
review believ announc futur pdp serv valid interest
htg technolog mark key catalyst htg stock
result htg gener rev y/i y/i
first nine month driven growth ruo profil servic pharma
collabor revenu came light busi lumpi
htg collabor develop servic revenu increas y/i
product revenu y/i came short due
time lumpi htg deliv loss better
guid htg expect hit midpoint revenue guid
y/i given favor year-end trend visibl collabor servic
edgeseq submiss spoke manag indic fda
pma submiss lung fusion edgeseq alkplu assay use aid
identif patient elig treatment alk-target drug like crizotinib
activ final time submiss sinc initi version
panel develop year ago htg identifi new set biomark
would like includ final version panel expect learn
statu htg new next-gen plu panel
price close busi novemb
htg global diagnost compani decentr
rna molecular profil proprietari
platform edgeseq pursu multipl ngs-
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
underappreci precis medicin
compani takeaway road
privileg host htg molecular ceo tj johnson cfo shaun
mcmean three day investor meet come away feel posit
compani posit precis medicin enabl less-crowd rna
profil market likelihood commerci one companion
diagnost assay trade revenu estim believ htg
underappreci precis medicin compani trade line dna
protein-focus instrument compani believ htg offer compel
platform well-posit enabl pharma compani develop novel therapi
upon fda clearanc first panel transit clinic compani reiter
buy rate pt use multipl revenu estim
million discount back two year discount rate share
instrument test panel gene express profil mirna sirna mrna
measur translat medicin diagnost applic pharma
compani academ molecular lab molecular profil analysi dna
rna protein target identifi express pattern genom chang
varieti patient sampl tissu blood urin etc htg look standard
make complex molecular profil easi use run sampl type
includ tini sampl ffpe tissu htg edg system autom sampl
librari prep profil thousand target enhanc versu
tradit approach look one target time htg custom either
purchas edgeseq instrument use veri/o lab send-out basi
retrospect sampl process custom assay develop pilot valid
sinc tissu demand high cancer diagnost limit tissu sampl often
challeng clinician research htg system provid sample-to-answ
fraction requir tissu compar technolog tissu trend
move surgic resect needl biopsi believ htg edgeseq
increas advantag process small sampl htg solut use
amount tissu commonli use test method htg edge/edgeseq
capabl multipl tumor profil techniqu dna mutat rna express gene
fusion rearrang protein express copi number variat
htg custom valu simplifi extract purif system abil
work minut amount tissu high degre multiplex differenti
take despit slight miss revenu htg deliv encourag
updat highlight continu progress toward sign one companion
diagnost agreement pharma htg expand earli stage biopharma
pipelin project translat shot goal
futur cdx agreement htg appear improv visibl busi
head consid catalyst-rich
guid given htg visibl expand develop biopharma
precis diagnost partnership pdp program revenu pull-through
consum veri/o servic lab ruo profil servic htg expect
revenu come near midpoint vs prior guid
diagnost tool
io panel key compon htg menu expans august
htg launch edgeseq precis immuno-oncolog io panel view
excit panel launch differenti compani io panel seek
quantifi express gene enabl deep multiplex analysi
checkpoint inhibit immun phenotyp inflamm statu tumor biolog
sub-typ tini amount sampl htg deliv initi order custom
work cancer immunolog immunotherapi io panel research
go raw sampl sequencing-readi librari littl hour
hour hands-on time htg develop analyt modul use research
look provid lab complet solut empow precis medicin
local level believ combin oncolog biomark panel obp
io offer increas demand biopharma partner
figur htg launch gene i-o panel august consid key driver interest pharma
expect go/no go decis htg two activ pharma develop program
next quarter htg two activ pharma develop program pdp gear
toward develop launch ngs-base companion diagnost assay
support one drug program underway bm one addit unknown
pharma compani htg indic call deliv two custom cdx
assay pharma collabor util retrospect studi
across multipl clinic trial diseas indic htg expect hear next
quarter mayb sooner whether pharma collabor intend submit
drug fda time htg would submit cdx assay review
note pharma partner use htg assay multipl clinic trial thu
expect multipl go/no go decis collabor believ
announc futur pdp serv valid interest htg technolog
mark key catalyst htg stock price
diagnost tool
figur htg commerci multiplex gene express assay support research diagnost object
earli phase project equal shot goal htg indic call
earli phase molecular profil project on-going number
expect grow expand menu scale sale forc htg goal
activ earli phase project end number view
achiev pharma compani use htg ruo profil explor rna
express signatur correl drug respons htg look posit
strong tool earli drug develop cycl offer servic
biomark develop hope lead use later-stag clinic trial
given recent menu expans launch io panel plan launch two mous panel
sale add believ htg may abl add new earli phase project per
quarter earli phase project anoth shot goal futur cdx deal
near-term sourc revenu htg
diagnost tool
figur htg goal convert portion earli stage molecular profil project custom assay develop cdx agreement
custom companion dx panel develop key sourc revenu earli phase
project prove success identifi rna biomark interest htg may
ask build custom companion diagnost panel htg paid upon
achiev certain mileston may includ develop test
organ run complet clinic trial submit drug data
fda commerci understand collabor
agreement rang year durat htg recogn
revenu given uncertainti around mileston achiev expect htg
collabor revenu remain lumpi htg current two late-stag project
refer pharma develop project pdp motion includ one
bristol-my squibb anoth unnam lead pharma compani htg
indic call like hear next quarter whether
cdx collabor intend submit drug fda time htg would
submit cdx assay believ announc futur pdp serv
valid interest htg technolog key catalyst stock
cdx commerci key revenu inflect htg largest revenu
opportun eventu sale fda- approv companion dx test htg
worthi submit drug fda htg concurr submit
companion dx assay fda upon approv usual six process
htg pharma collabor may begin sell drug companion dx
individu elig treatment
diagnost tool
figur cdx commerci htg largest revenu opportun take longest achiev
frame htg cdx revenu opportun htg success develop cdx
assay believ compani price assay around test
await clariti regard specif diseas indic htg pharma
partner target frame htg opportun around number indic
could relev htg current assay menu includ lymphoma non-smal
cell lung cancer immuno-oncolog assum price
lymphoma patient elig therapeut drug lung cancer elig
annual revenu opportun htg captur drug sale
patient lymphoma non-smal cell lung cancer would repres
annual cdx revenu opportun htg believ develop
cdx immuno-oncolog drug present larg revenu opportun estim
individu elig io drug repres annual cdx
test opportun full scale annual revenu opportun assum
captur i-o drug sale
htg cheap play precis medicin believ compani enabl
practic precis medicin look exposur precis
medicin htg look like cheap bet revenu estim vs dna
enabl protein enabl concept precis
medicin serv mega-trend stock coverag
univers one certainli import enabl
beneficiari precis medicin lab benefit trend demand
custom assay research clinic set heighten believ
era precis medicin earli inning like drive life scienc
diagnost compani higher enter final leg move
look new technolog new applic new improv assay better
diagnost tool
econom payor custom assay benefit life scienc particip
research clinic market
sale forc expand pace htg current employ roughli sale rep
recent made key hire pharma team htg intend make opportunist
hire europ anticip anoth modest sale forc expans
though note htg doesnt requir larg sale forc given narrowli
target pharma major cancer center htg indic low level
sampl need run assay continu serv key sell point sale rep
target larg refer laboratori larg patholog center larg cancer center
road compani intend target commun smaller lab
figur htg look roll least new ruo assay year
htg compet blue ocean market htg beneficiari call scarciti
valu given differenti less-crowd rna market genom
expect remain forefront precis medicin expect genom
compani shift toward multi-mark multi-om approach includ
rna protein biomark rna market advanc surmis sequenc
compani like explor htg acquisit target given sequenc
key compon htg workflow given compani technolog sequenc
agnost believ multipl potenti buyer htg road
htg target expans liquid biopsi htg edgeseq platform work
cell line plasma/serum paxgen blood tube dna stabil purifi
rna paraffin-embed ffpe tissu sampl htg primari sampl type
consid debat import sampl type cancer diagnost
ffpe remain htg lead sampl type compani indic
revenu came custom run liquid biopsi applic htg
develop addit panel expand reach liquid biopsi target
detect cell-fre rna circul lymphocyt exosom circul tumor
cell liquid biopsi sampl type includ plasma/serum paxgen isol
exosom sort cell htg expect primari tissu remain domin
sampl type initi patient diagnosi expect liquid biopsi prove disrupt
patient monitor residu diseas screen near term
diagnost tool
look revenu inflect year model
revenu y/i though
see upsid estim htg advanc one earli phase project pdp
agreement expect sale cdx assay provid valuabl revenu stream
begin though await announc one pdp cdx
assay fda incorpor model expect htg follow
natur trajectori instrument/assay compani target
time consum sale outpac lower margin instrument servic revenu
htg burn quarter exit cash
fda submiss htg edgeseq fda submiss delay may work
compani favor spoke manag indic pma
submiss lung fusion edgeseq alkplu assay use aid
identif patient elig treatment alk-target drug like crizotinib
activ compani final time submiss given
initi version panel develop year ago htg sinc
identifi number new relev biomark would like includ final
version panel expect learn statu improv
plu panel
htg tap former celgen exec svp/chief scientif offic htg recent hire
former celgen execut dr maureen cronin post svp/chief scientif
offic dr cronin previous serv execut director strateg inform
manag celgen svp research product
develop foundat medicin vice-president translat
research senior director technolog develop
genom health dr cronin instrument develop
genom health oncotyp dx breast test lead new program aim toward
develop breast cancer assay expect learn
firali deal look beyond oncolog autoimmun diseas htg
announc deal france-bas biotech firali enabl firali develop
sequencing-bas theranost test predict rheumatoid arthriti patient respons
anti-tnf tumor necrosi factor alpha therapi humira view
compel applic outsid htg oncolog focu success
think could bode well addit use autoimmun diseas
time increas breadth test applic beyond oncolog htg support
firali instrument reagent kit support commerci plan
mous panel expand htg menu htg announc august plan
launch htg edgeseq mous microrna whole transcriptom assay htg
edgeseq mous messeng rna tumor respons assay htg launch
two panel respons rise custom demand earli translat
studi use mous model high volum htg expect panel yield
higher volum sampl type may drive instrument placement htg indic
due high concord mous human sampl research
ask htg mous panel initi test de-risk futur trial run human
takeaway three-day roadshow
consist instrument compani univers htg gm profil
includ higher gm consum margin instrument margin
lower servic margin room scale matur htg expect product
consum instrument margin servic margin compar
htg see path sustain time
diagnost tool
htg goal deliv four new ruo panel year one per quarter
new ruo panel typic take month develop
htg hold cash balanc sheet think fund
oper
htg expect grow european busi approxim
ad dedic eu resourc need
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
diagnost tool
